Impact of tumor number on the efficacy of lenvatinib in borderline resectable hepatocellular carcinoma.

IF 1.8 3区医学 Q2 SURGERY

Langenbeck's Archives of Surgery Pub Date : 2025-10-03 DOI:10.1007/s00423-025-03867-6

Naokazu Chiba, Takumi Seichi, Masashi Nakagawa, Shigeto Ochiai, Takahiro Gunji, Toru Sano, Junichi Taira, Katsuya Kitamura, Shigeyuki Kawachi

{"title":"Impact of tumor number on the efficacy of lenvatinib in borderline resectable hepatocellular carcinoma.","authors":"Naokazu Chiba, Takumi Seichi, Masashi Nakagawa, Shigeto Ochiai, Takahiro Gunji, Toru Sano, Junichi Taira, Katsuya Kitamura, Shigeyuki Kawachi","doi":"10.1007/s00423-025-03867-6","DOIUrl":null,"url":null,"abstract":"Background: The global incidence of hepatocellular carcinoma (HCC) is steadily rising, and the disease is associated with poor survival outcomes. As a multicentric cancer with a high recurrence rate, surgical resection alone is often not sufficient for a curative treatment. This study aimed to identify factors that predict its efficacy in patients with HCC classified as borderline resectable according to the BR-HCC Expert Consensus 2023.Methods: This study retrospectively analyzed 30 patients with borderline resectable HCC who were treated with Lenvatinib as their initial therapy. The study retrospectively examined the predictive factors for the disease control rate (DCR) following Lenvatinib treatment. A secondary objective was to evaluate the impact of the treatment on overall survival and identify cases that showed a significant response.Results: The presence of a single tumor was found to be the only independent predictive factor for treatment response. The 5-year survival rate for patients in the stable disease (SD) and partial response (PR) groups was 33.3%, which was significantly higher than that of the progressive disease (PD) group. Of the six patients who achieved a PR with Lenvatinib, four had a single tumor with vascular or biliary invasion or extrahepatic metastasis. Similarly, the two patients who underwent radical resection after Lenvatinib treatment also had a single tumor with these characteristics.Conclusions: The presence of a single tumor may be a crucial factor in the use of Lenvatinib for borderline HCC.","PeriodicalId":17983,"journal":{"name":"Langenbeck's Archives of Surgery","volume":"410 1","pages":"289"},"PeriodicalIF":1.8000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12494618/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Langenbeck's Archives of Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00423-025-03867-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The global incidence of hepatocellular carcinoma (HCC) is steadily rising, and the disease is associated with poor survival outcomes. As a multicentric cancer with a high recurrence rate, surgical resection alone is often not sufficient for a curative treatment. This study aimed to identify factors that predict its efficacy in patients with HCC classified as borderline resectable according to the BR-HCC Expert Consensus 2023.

Methods: This study retrospectively analyzed 30 patients with borderline resectable HCC who were treated with Lenvatinib as their initial therapy. The study retrospectively examined the predictive factors for the disease control rate (DCR) following Lenvatinib treatment. A secondary objective was to evaluate the impact of the treatment on overall survival and identify cases that showed a significant response.

Results: The presence of a single tumor was found to be the only independent predictive factor for treatment response. The 5-year survival rate for patients in the stable disease (SD) and partial response (PR) groups was 33.3%, which was significantly higher than that of the progressive disease (PD) group. Of the six patients who achieved a PR with Lenvatinib, four had a single tumor with vascular or biliary invasion or extrahepatic metastasis. Similarly, the two patients who underwent radical resection after Lenvatinib treatment also had a single tumor with these characteristics.

Conclusions: The presence of a single tumor may be a crucial factor in the use of Lenvatinib for borderline HCC.

查看原文本刊更多论文

肿瘤数目对lenvatinib治疗交界性可切除肝癌疗效的影响。

背景：肝细胞癌（HCC）的全球发病率正在稳步上升，并且该疾病与较差的生存结果相关。作为一种复发率高的多中心癌，单纯手术切除往往不足以治愈。本研究旨在确定根据BR-HCC专家共识2023分类为边缘可切除的HCC患者预测其疗效的因素。方法：本研究回顾性分析了30例以Lenvatinib作为初始治疗的边缘性可切除HCC患者。本研究回顾性检查Lenvatinib治疗后疾病控制率（DCR）的预测因素。第二个目标是评估治疗对总生存期的影响，并确定显示显着反应的病例。结果：发现单一肿瘤的存在是治疗反应的唯一独立预测因素。稳定期（SD）组和部分缓解（PR）组患者的5年生存率为33.3%，明显高于进展性疾病（PD）组。在使用Lenvatinib达到PR的6例患者中，4例为单一肿瘤伴血管或胆道侵犯或肝外转移。同样，两例在Lenvatinib治疗后进行根治性切除的患者也有一个具有这些特征的肿瘤。结论：单一肿瘤的存在可能是Lenvatinib治疗交界性HCC的关键因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Langenbeck's Archives of Surgery 医学-外科

CiteScore

3.30

自引率

8.70%

发文量

342

审稿时长

4-8 weeks

期刊介绍： Langenbeck''s Archives of Surgery aims to publish the best results in the field of clinical surgery and basic surgical research. The main focus is on providing the highest level of clinical research and clinically relevant basic research. The journal, published exclusively in English, will provide an international discussion forum for the controlled results of clinical surgery. The majority of published contributions will be original articles reporting on clinical data from general and visceral surgery, while endocrine surgery will also be covered. Papers on basic surgical principles from the fields of traumatology, vascular and thoracic surgery are also welcome. Evidence-based medicine is an important criterion for the acceptance of papers.